Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients

• Published in: Hepatology research Vol. 43; no. 5; pp. 495 - 501
• Main Authors: Feng, Lijuan, Niu, Yujian, Chen, Hong, You, Hong, Zang, Yunjin, Li, Li, Shan, Shan, Tan, Yule, Jia, Jidong, Shen, Zhongyang
• Format: Journal Article
• Language: English
• Published: Netherlands Blackwell Publishing Ltd 01.05.2013
• Subjects: Hepatitis B virus; hepatitis B virus recurrence; hepatitis B virus vaccine; liver transplantation
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1111/j.1872-034X.2012.01102.x

Aim To compare the immunogenicity of two modified hepatitis B virus (HBV) vaccination schedules in liver transplant recipients. Hepatitis B immunoglobulin (HBIG) in combination with nucleoside/nucleotide analogs (NUCs) is the recommended prophylaxis for preventing HBV recurrence following liver transplantation (LT). However, HBIG treatment is expensive. Active immunization with hepatitis B vaccine would be a preferable alternative prophylaxis to replace HBIG treatment. However, the overall response rate to standard vaccination (given at months 0, 1 and 6) is relatively low in immune‐compromised patients. Methods Two cohorts of 114 subjects were immunized with recombinant HBV vaccine containing S‐antigen. The patients in the rapid schedule group were immunized with 40 μg HBV vaccine at months 0, 1, 2 and 3, and with 20 μg at months 4, 5 and 6. The patients in the accelerated schedule group were immunized with 40 μg of HBV vaccine at days 0, 7, 14 and 28, and 20 μg at months 2, 3 and 4. Results The overall response rate was 16.7% (19/114) and all responders discontinued HBIG injection and only one patient developed HBV recurrence. The response rate was 24.6% (14/57) and 8.8% (5/57) in the rapid vaccination and the accelerated vaccination schedules, respectively (P = 0.024). Conclusion HBV vaccination may induce endogenous anti‐HBs to replace HBIG in selected patients. Vaccination schedules may influence vaccine response, and individual optimization may improve response rate to HBV vaccination.